RCKT Rocket Pharmaceuticals, Inc.
$2.45▲ +7.46%
Healthcare
Other
Volume 2.05M
Avg Volume (10D) 1.90M
Key Metrics & Fundamentals
Market Cap
$268.95M
P/E Ratio
–
Div Yield
0.00%
52W Range
2.17 - 5.45
% vs 50 MA
-18.93%
% vs 200 MA
-29.39%
RSI-14
45.3
MACD Histogram
+0.0400
Beta (1Y vs SPY)
1.73
Free Cash Flow
-$39.62M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$43.78M
COGS
–
Operating Exp
$46.92M
Operating Income
-$46.92M
EBIT
-$46.92M
Pretax Income
$131.84M
Net Income
$123.21M
EPS (Diluted)
1.08
Price & Volume History
Loading chart…
Recent News
Rocket Pharmaceuticals to Participate in Chardan’s 10th Annual Healthcare Conference
Business Wire · Oct 15, 2026 7:00 AM ET
Rocket Pharmaceuticals Shares Rise After Goldman Sachs Upgrade
MT Newswires · Oct 8, 2026 3:11 PM ET
Goldman Sachs Upgrades Rocket Pharmaceuticals to Neutral From Sell, Price Target is $4
MT Newswires · Oct 8, 2026 7:17 AM ET
Rocket Pharmaceuticals shares rise 4% after securing access to $150 million credit facility
Proactive · Oct 7, 2026 11:36 AM ET
Rocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor Webinar
Business Wire · Oct 7, 2026 9:36 AM ET
MARKETS LIVE: Wall Street ends lower as 30-year Treasury yield hits 2002 high
Proactive · Oct 7, 2026 7:10 AM ET
Rocket receives $150m credit facility to advance cardiovascular portfolio
Pharmaceutical Technology · Oct 7, 2026 6:42 AM ET
Rocket Pharmaceuticals Details RP-A501 Pivotal Plan After Safety Reset
MarketBeat · Oct 6, 2026 10:02 PM ET
Rocket Secures Credit Facility From Hercules Capital
MT Newswires · Oct 6, 2026 4:48 PM ET
Rocket Pharmaceuticals Secures Strategic Credit Facility for Up to $150 Million from Hercules Capital
Business Wire · Oct 6, 2026 4:12 PM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See RCKT's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.